Addressing Drug Diversion

Size: px
Start display at page:

Download "Addressing Drug Diversion"

Transcription

1 Webinar Objectives Addressing Drug Diversion Bernice Burkarth, MD, HMDC, FAAHPM October12, 2017 At the completion of this Webinar, participants will be able to: Identify tools and strategies to minimize drug diversion in the practice of hospice and palliative care Discuss electronic tools used in prescribing controlled substances in hospice and palliative care Discuss strategies to identify and address both patient and family drug diversion CDC Prescriber Education PRESCRIPTION PAIN KILLER OVERDOSES AT EPIDEMIC LEVELS CDC press release November 1, 2011 Overdoses involving prescription painkillers are at epidemic levels and now kill more Americans than heroin and cocaine combined, CDC Director Thomas Frieden, M.D., M.P.H. The SCOPE of PAIN Safe and Competent Opioid Prescriber Education Boston University COPE Collaborative Opioid Prescribing Education Substance Abuse and Mental Health Services Administration American Academy of Addiction Psychiatry The 10 Steps of Universal Precautions in Pain Medicine 1. Make a Diagnosis With Appropriate Differential 2. Psychological Assessment, Including Risk of Addictive Disorders 3. Informed Consent 4. Treatment Agreement 5. Pre or Post Intervention Assessment of Pain Level and Function The 10 Steps of Universal Precautions in Pain Medicine 6. Appropriate Trial of Opioid Therapy With or Without Adjunctive Medication 7. Reassessment of Pain Score and Level of Function 8. Regularly Assess the "4 A's" of Pain Medicine 9. Periodically Review Pain Diagnosis and Comorbid Conditions, Including Addictive Disorders 10. Documentation Gourlay D, Heit HA, Universal precautions in pain medicine: The Treatment of Chronic Pain With or Without the Disease of Addiction. Medscape Neurology. 2005;7(1) 2005 Medscape Gourlay D, Heit HA, Universal precautions in pain medicine: The Treatment of Chronic Pain With or Without the Disease of Addiction. Medscape Neurology. 2005;7(1) 2005 Medscape 5 6 1

2 Opioid Risk Assessments Tools: prior to initiating long term therapy ORT (Opioid Risk Tool) SOAPP R (The Screener and Opioid Assessment for Patients with Pain Revised ) SISAP (Screening Instrument for Substance Abuse Potential) DIRE (The Diagnosis, Intractability, Risk, Efficacy) tool Opioid Risk Assessments Tools: monitoring for signs of opioid misuse in patients receiving long term opioid therapy PDUQ p (Prescription Drug Use Questionnaire patient version) COMM (Current Opioid Misuse Measure) PMQ (Patient Medication Questionnaire) Opioid Risk Assessments Tools: monitoring for signs of opioid misuse in patients receiving long term opioid therapy PADT (Pain Assessment and Documentation Tool) ABC (Action Behavior Checklist) Patient Provider Agreement Include as part of informed consent Incorporate drug disposal guidelines and expectations Inclusion of caregivers in agreement and accountability the "4 A's" of Pain Medicine Analgesia Activity Adverse effects Aberrant behaviors Pharmacologic Advances Abuse Deterrent Preparations Kenneth L. Kirsh, PhD; Steven D. Passik, PhD. Managing Drug Abuse, Addiction, and Diversion in Chronic Pain: The 4 A's for Ongoing Monitoring Medscape Neurology. 2005;7(2) 2005 Medscape 11 2

3 Electronic Tools Electronic Prescribing Organizational Processes Pill counts at every visit Providing lock boxes Random urine drug screen Prescription Drug Monitoring Programs 14 Organizational Processes Prescribing in smaller quantities Providing patient and caregiver education on safe storage of medications Providing patient and caregiver education on safe drug disposal FDA guidance Take back programs Medicines recommended for disposal by Abstral tablets (sublingual) Fentanyl Actiq oral transmucosal lozenge * Fentanyl Citrate Arymo ER, tablets (extended release) Morphine Sulfate Avinza capsules (extended release) Morphine Sulfate Belbuca soluble film (buccal) Buprenorphine Buprenorphine, tablets (sublingual) * Buprenorphine Buprenorphine ; Naloxone Buprenorphine ; Naloxone, tablets (sublingual) * Butrans transdermal patch system Buprenorphine ringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend Daytrana transdermal patch system Methylphenidate Demerol, tablets * Meperidine Demerol, oral solution * Meperidine Diastat/Diastat AcuDial, rectal gel [for disposal instructions: click on link, then go to "Label Diazepam information" and view current label] Dilaudid, tablets * Hydromorphone Dilaudid, oral liquid * Hydromorphone Dolophine tablets * Methadone Duragesic patch (extended release) * Fentanyl Embeda capsules (extended release) Morphine Sulfate; Naltrexone Exalgo tablets (extended release) Hydromorphone 17 ngsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend Fentora tablets (buccal) Fentanyl Citrate Hysingla ER tablets (extended release) Hydrocodone Bitartrate Kadian capsules (extended release) Morphine Sulfate Methadone, oral solution * Methadone Methadose, tablets * Methadone Morphabond (extended release) Morphine Sulfate Morphine Sulfate, tablets (immediate release) * Morphine Sulfate Morphine Sulfate oral solution * Morphine Sulfate MS Contin tablets (extended release) * Morphine Sulfate Nucynta ER (extended release) Tapentadol 18 suringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend 3

4 Onsolis (PDF 297KB), soluble film (buccal) Fentanyl Citrate Opana, tablets (immediate release) Oxymorphone Opana ER (extended release) Oxymorphone Oxecta, tablets (immediate release) Oxycodone Oxycodone, capsules Oxycodone Oxycodone oral solution Oxycodone Oxycontin tablets (extended release) Oxycodone Percocet, tablets * Acetaminophen; Oxycodone Percodan, tablets * Aspirin; Oxycodone Suboxone film (sublingual) Targiniq ER (extended release) Vantrela ER, tablets (extended release) Xartemis XR tablets Xtampza ER capsules (extended release) Xyrem oral solution Zohydro ER capsules (extended release) Zubsolv tablets (sublingual) Buprenorphine ; Naloxone Oxycodone ; Naloxone Hydrocodone Bitartrate Oxycodone ; Acetaminophen Oxycodone Sodium Oxybate Hydrocodone Bitartrate Buprenorphine ; Naloxone 19 nsuringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend uringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend 20 Challenges: Whose drugs are they? In most states, hospices have little control over the pills after a patient dies. The U.S. Drug Enforcement Administration encourages hospice staff to help families destroy leftover medications, but the agency forbids those staff members from destroying the meds themselves unless that is allowed by state law. Leftover pills belong to the family, which has no legal obligation to destroy them or give them up Bailey, M. (2017, August 21). Dying at home in pain doesn t keep relatives from stealing the pills. Washingtonpost.com. Retrieved August 29, 2017, from science/dying at home in pain doesnt keep relatives from stealing the pills/2017/08/18/d262b9ba e7 902a 2a9f2d808496_story.html?utm_term=.4d33df79083f Getting Legislative Help Ohio Delaware New Jersey South Carolina These states have passed laws giving hospice staff authority to destroy unused drugs after patients die. Bailey, M. (2017, August 21). Dying at home in pain doesn t keep relatives from stealing the pills. Washingtonpost.com. Retrieved August 29, 2017, from science/dying at home in pain doesnt keep relatives from stealing the pills/2017/08/18/d262b9ba e7 902a 2a9f2d808496_story.html?utm_term=.4d33df79083f NHPCO on the Frontline: Supporting a National Policy and Uniform Set of Practices NHPCO has already drafted legislation and has been working with Congress to expand the ability of hospice professionals to take a more active role in helping families dispose of these drugs. Getting Legislative Help Advocating for cooperation with agencies that limit smaller, but more frequent prescription fills Medicaid VA NHPCO Response to KHN/Post. Edo Banach Responds to Kaiser Health News August 22,

5 Documentation Patient assessment Pain assessment The 4 A s of pain medicine Harris, DG. Management of Pain in Advanced Disease. British Medical Bulletin 2014, Teoha, Penelope J., Camm, Christian F. NICE Opioids in Palliative Care A Guideline Summary. Penelope J. Teoha, Christian F. Camm BA (Hons.). Annals of Medicine and Surgery 2012; 1(1): Portenoy, Russell K., Sibirceva, Una,Smout, Randall, Horn, Susan, Connor, Stephen, Blum, Ronald H.. Opioid Use and Survival at the End of Life: A Survey of a Hospice Population. Spence, Carol, Fine, Perry G. Journal of Pain and Symptom Management. Vol. 32 No. 6 December 2006 Review of medication safety guidelines 25 QUESTIONS Common Elements in Guidelines for Prescribing Opioids for Chronic Pain. CDC. National Center for Injury Prevention and Control Division of Unintentional Injury Prevention Edlund, Mark J., Martin Bradley C., Devries, Andrea, Fan, Ming Yu, Brennan Braden, Jennifer, Sullivan, Mark D. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain January ; 26(1): 1 8 Chakravarthy Bharath, Shah, Shyam, Lotfipour, Shahram. Prescription Drug Monitoring Programs and Other Interventions to Combat Prescription Opioid Abuse. Western Journal of Emergency Medicine. Volume XIII, NO. 5 : November 2012 Throckmorton, Douglas C. Opioid Prescribing Practices and Pain Management: Role of FDA. American Academy of Hospice and Palliative Care Medicine. October, Gardiner, Clare; Gott, Merryn; Ingleton, Christine; Hughes, Philippa; Winslow, Michelle;. Bennett, Michael I. Attitudes of Health Care Professionals to Opioid Prescribing in End of Life Care: A Qualitative Focus Group Study. Journal of Pain and Symptom Management. Vol. 44 No. 2 August 2012 Bailey, M. (2017, August 21). Dying at home in pain doesn t keep relatives from stealing the pills. Washingtonpost.com. Retrieved August 29, 2017, from science/dying athome in pain doesnt keep relatives from stealing thepills/2017/08/18/d262b9ba e7 902a 2a9f2d808496_story.html?utm_term=.4d33df79083f Universal Precautions for Drug Misuse and Diversion in Hospice and Palliative Care Could an Ounce of Prevention Be Worth a Pound of Cure? (FR434) Cass, CleanneThomson, RuthBledsoe, RebeccaDurkin, Elizabeth et al. Journal of Pain and Symptom Management, Volume 49, Issue 2, Kenneth L. Kirsh, PhD; Steven D. Passik, PhD. Managing Drug Abuse, Addiction, and Diversion in Chronic Pain: The 4 A's for Ongoing Monitoring Medscape Neurology. 2005;7(2) 2005 Medscape Dmitry M. Arbuck, MD, Timothy J. Atkinson, PharmD, BCPS, Martin D. Cheatle, PhD, Amber Fleming, PsyD, HSPP, Gary W. Jay, MD, Lee Kral, PharmD, Amanda Macone, MD, Jordan L. Newmark, MD, Chinyere Ogbonna, MD, MPH, James A.D. Otis, MD, MBA, Tracey L. Perkins, RN, MSN, FNP C, Jennifer H. Scruggs, RN, MSN, ANP BC, Tejinder Swaran Singh, MD, Forest Tennant, MD, DrPH, Bob Twillman, PhD, Opioid Prescribing and Monitoring: How to Combat Opioid Abuse and Misuse Responsibly 5

6 Edlund M, Martin B, Russo J, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non cancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):

Disposal of Unused Medicines: What You Should Know

Disposal of Unused Medicines: What You Should Know 1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended

More information

Disposal of Unused Medicines: What You Should Know

Disposal of Unused Medicines: What You Should Know 1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite

More information

How To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist

How To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative

More information

Disposal by Flushing of Certain Unused Medicines: What

Disposal by Flushing of Certain Unused Medicines: What Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List

More information

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)

More information

Carefirst. +.V Family of health care plans

Carefirst. +.V Family of health care plans Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,

More information

Opioid Management Program October 2018

Opioid Management Program October 2018 Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

Opioid Management Program May 2018

Opioid Management Program May 2018 Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily

More information

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Pharmacy Medical Necessity Guidelines: Opioid Analgesics Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Pequot Health Care Opioid Analgesic Quantity Program*

Pequot Health Care Opioid Analgesic Quantity Program* Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits

More information

Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)

Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have

More information

Prior Authorization for Opioid Products Indicated for Pain Management

Prior Authorization for Opioid Products Indicated for Pain Management Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax

More information

Prior Authorization Guideline

Prior Authorization Guideline Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011

More information

APPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION

APPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms

More information

Pharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers

Pharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers Pharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers James P. Rathmell, M.D. Chair, Department of Anesthesiology, Perioperative and Pain Medicine

More information

QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA

QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release

More information

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335

More information

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is

More information

: Opioid Quantity Limits

: Opioid Quantity Limits March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3053-7 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing

More information

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise

More information

Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018

Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting

More information

EXTENDED RELEASE OPIOID DRUGS

EXTENDED RELEASE OPIOID DRUGS RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),

More information

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Opioid Analgesics. Recommended starting dose for opioid-naïve patients Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote

More information

Opioid Prescribing Guidelines for Patients in the Emergency Department

Opioid Prescribing Guidelines for Patients in the Emergency Department Opioid Prescribing Guidelines for Patients in the Emergency Department and Immediate Care Centers These guidelines are meant to assist clinicians in treating patients with acute and chronic pain in the

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next

More information

Prior Authorization Opioid Overutilization 2017

Prior Authorization Opioid Overutilization 2017 Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE

More information

STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)

STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules) Carelirst. +.V Family of health care plans cvs caremarktm STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME* (generic)

More information

Xyrem (Sodium Oxybate)

Xyrem (Sodium Oxybate) Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization

More information

Morphine Sulfate Hydromorphone Oxymorphone

Morphine Sulfate Hydromorphone Oxymorphone Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone

More information

Preventing Prescription Opioid Misuse Among Student Athletes

Preventing Prescription Opioid Misuse Among Student Athletes Preventing Prescription Opioid Misuse Among Student Athletes Massachusetts is in the midst of an opioid epidemic. Athletes in particular, due to their risk of injury and the resulting pain, may be at risk

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018

Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Extended-release (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1,

More information

Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital

Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium

More information

Blueprint for Prescriber Continuing Education Program

Blueprint for Prescriber Continuing Education Program CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting

More information

Prescription Drug Abuse: Colorado and Nationwide

Prescription Drug Abuse: Colorado and Nationwide Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?

More information

Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable

Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4 6pm SPEAKERS Charles Argoff, MD, FABPM Michael Brennan, MD, FACP, FASAM Jeffrey Gudin, MD Presenter Disclosure Information The

More information

1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I

1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University

More information

Stephanie E. Hughes, P.E. (408)

Stephanie E. Hughes, P.E. (408) Stephanie E. Hughes, P.E. (408) 499-9271 steifehughes@yahoo.com www.stephaniehughes.net Learning Objectives Understand the environmental and social burdens of pharmaceutical waste Recognize the complexity

More information

Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team

Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team Cheryl L Mejta, Ph.D. Nancy H Burley, Ed.D. Serena Wadhwa, Psy. D., LCPC, RYT, CADC Objectives Identify

More information

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last

More information

Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain

Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain Medication Policy Manual Topic: Extendedrelease (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1, 2018 Committee Approval Date: January 19. 2018 Next Review Date: December

More information

Opioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM

Opioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM Western Occupational Health Conference September 14, 2012 Opioid - Use & Misuse Scott Levy, MD MPH FACOEM Steven Feinberg, MD, MPH Disclosure Information Western Occupational Health Conference 2012 Steven

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Opiate/Benzodiazepine/Muscle Relaxant Combinations

Opiate/Benzodiazepine/Muscle Relaxant Combinations Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:

More information

Interprofessional Webinar Series

Interprofessional Webinar Series Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation

More information

Equianalgesic Dosing of Opioids for Pain Management

Equianalgesic Dosing of Opioids for Pain Management PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management

More information

Risk Reduction Strategies in Pain Management

Risk Reduction Strategies in Pain Management Risk Reduction Strategies in Pain Management Melissa J. Durham, PharmD, MACM, BCACP, DAAPM Assistant Professor of Clinical Pharmacy USC School of Pharmacy Clinical Pharmacist, The USC Pain Center Learning

More information

Methadone. Description

Methadone. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Opioid Management Health and Safety Program POLICY NUMBER: PHARMACY-34 EFFECTIVE DATE: 6/2007 LAST REVIEW DATE: 07/01/2018 If the member s subscriber contract excludes coverage for a specific

More information

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be

More information

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care In August 2014, the Food and Drug Administration (FDA) updated the Extended- Release/Long Acting Opioids REMS Blueprint (BP). CO*RE has

More information

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen

More information

2/21/2018. What are Opioids?

2/21/2018. What are Opioids? Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting

More information

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy

More information

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta

More information

15 mg morphine 10 mg hydrocodone

15 mg morphine 10 mg hydrocodone Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually

More information

Drug Use Evaluation: Short Acting Opioids (SAO)

Drug Use Evaluation: Short Acting Opioids (SAO) Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl

More information

Extended Release Opioid Drugs

Extended Release Opioid Drugs Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: January 1, 2019 Subject: Extended Release Opioid Drugs Page:

More information

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA

More information

Opioid Prescription and Illicit Drug Overdoses: On the Rise

Opioid Prescription and Illicit Drug Overdoses: On the Rise Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define

More information

``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts

``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts Opioids Effective Case Management Opioids RELEVANCE IN WORKERS COMP Opioids are a diverse group of drugs that represent the strongest pain medications available. They are frequently prescribed for pain

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Extended Release Opioid Drugs

Extended Release Opioid Drugs Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 14 Last Review Date: March 16, 2018 Extended

More information

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl

More information

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

New Hampshire Healthy Families CLINICAL POLICY

New Hampshire Healthy Families CLINICAL POLICY New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:

More information

Breakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights

Breakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights Breakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights Steven Wong, MD Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, UCLA David Geffen School of Medicine

More information

Recognizing Narcotic Abuse and Addiction and Helping Those With It

Recognizing Narcotic Abuse and Addiction and Helping Those With It Recognizing Narcotic Abuse and Addiction and Helping Those With It Michael McNett, MD Medical Director for Chronic Pain Member, WI Med Society Opioid Subcommittee Ancient History 1995: OxyContin approved

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

OPIOID IDENTIFICATION GUIDE

OPIOID IDENTIFICATION GUIDE OPIOID IDENTIFICATION GUIDE WHAT ARE OPIOIDS, PRESCRIPTION PAINKILLERS, OR NARCOTICS? Rx Rx Rx Rx The Prescription Playbook Rx The Prescription Playbook is an education and awareness campaign for parents

More information

Drug Formulary Commission

Drug Formulary Commission Drug Formulary Commission Bureau of Health Care Safety and Quality Department of Public Health December 15, 2016 Slide 1 Presentation Agenda Draft Formulary (105 CMR 720) Schedule Amendments Comments Guidance

More information

Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4:

Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: 279-283. POLICY FORUM OxyContin, the FDA, and Drug Control Gary M. Reisfield, MD One percent of people will

More information

Can Chronic Opioid Therapy Be Used Safely and Effectively for the Treatment of Chronic Pain? Charles E. Argoff, MD, CPE

Can Chronic Opioid Therapy Be Used Safely and Effectively for the Treatment of Chronic Pain? Charles E. Argoff, MD, CPE Can Chronic Opioid Therapy Be Used Safely and Effectively for the Treatment of Chronic Pain? Charles E. Argoff, MD, CPE Disclosure Consultant/Independent Contractor Depomed, Teva, Endo, Purdue, Quest,

More information

Session VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty

Session VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty Presenter Disclosure Information SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4:15 5pm Getting the Most Clinical Insights from Specific ER/LA Product Information Sources SPEAKERS

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy

More information

Opioid Overview Admiral Brett P. Giroir, M.D.

Opioid Overview Admiral Brett P. Giroir, M.D. A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE

More information

Abuse Deterrent Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017

Abuse Deterrent Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017 Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017 Introduction 1,2 Dilemma: Providing balance between providing appropriate access to opioid products in patients who truly need them AND addressing

More information

Prescription Opioid Painkiller Public Opinion Poll

Prescription Opioid Painkiller Public Opinion Poll Prescription Opioid Painkiller Public Opinion Poll August, 2017 OBJECTIVES The overall objective of this research was to collect attitudes and views of prescription opioid painkillers among adults in Illinois.

More information

Extended-Release and Long- Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Presenter: Affiliation:

Extended-Release and Long- Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Presenter: Affiliation: Extended-Release and Long- Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Presenter: Affiliation: Faculty Disclosure FACULTY place your disclosure information on this slide Thank

More information

PAIN CONTROL IN THE PATIENT WITH ACUTE/CHRONIC PAIN JAY E. OLSSON,DO AOBPMR DCAQPM ABPMR ABPM

PAIN CONTROL IN THE PATIENT WITH ACUTE/CHRONIC PAIN JAY E. OLSSON,DO AOBPMR DCAQPM ABPMR ABPM PAIN CONTROL IN THE PATIENT WITH ACUTE/CHRONIC PAIN JAY E. OLSSON,DO AOBPMR DCAQPM ABPMR ABPM Disclaimers Speaker Bureau Avanir Pharmaceuticals Nuedexta Pfizer Inc. Embeda Lyrica FOCUS Pharmacologic interventions

More information

NATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND

NATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough

More information

Conversion chart from fentanyl to opana er

Conversion chart from fentanyl to opana er Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),

More information

Extended Release Opioid Drugs

Extended Release Opioid Drugs Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 13 Last Review Date: December 8, 2017 Extended

More information

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,

More information

4/3/2018. The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers. Learning Objectives

4/3/2018. The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers. Learning Objectives The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers Melissa Durham Tania Gregorian Vlada Manzur Learning Objectives Describe current issues

More information

The Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.

The Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D. The Unseen Consequences of Prescription Drug Abuse Stephen Loyd, M.D. Stephen Loyd, M.D. Receives no commercial support, in any form, from pharmaceutical companies or anyone else Medical Director for Substance

More information

Education Program for Prescribers and Pharmacists

Education Program for Prescribers and Pharmacists Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)

More information

Technician Tutorial: Scheduled Drugs

Technician Tutorial: Scheduled Drugs (Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part

More information

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017 Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial

More information

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine

More information